Industry analysis highlights Eli Lilly's strategic advantages over rival Novo Nordisk in the rapidly expanding obesity treatment sector, positioning the pharmaceutical giant as the primary beneficiary of the GLP-1 gold rush.

Billionaire investor Stanley Druckenmiller is reportedly betting on Rhythm Pharmaceuticals, believing the company can treat a specific form of obesity that Eli Lilly and Novo Nordisk cannot. This highlights a new investment focus in the pharmaceutical sector.

Bristol-Myers Squibb (BMY) has committed $2.3 billion to investments in Texas, while Eli Lilly (LLY) has achieved significant success in the United Kingdom market.

An analysis explores the possibility of pharmaceutical giant Eli Lilly surpassing SpaceX in market valuation by the end of 2026, considering their respective growth trajectories and market positions.

This article evaluates UnitedHealth Group (UNH) and Eli Lilly and Company (LLY) to assess which healthcare stock offers a more attractive dividend for investors.

OmniAb has announced a new collaboration and license agreement with pharmaceutical giant Eli Lilly.

The Canada Revenue Agency (CRA) is reportedly auditing pharmaceutical giant Eli Lilly Canada's taxes, with a lawsuit revealing the ongoing investigation.

Professor Kirsi Pietiläinen states that Eli Lilly is correct in asserting that Finland lacks a comprehensive obesity policy, adding that the national obesity program should not have been terminated.

Eli Lilly is reportedly expanding its research and development efforts to create a variety of weight loss drugs tailored to different patient needs and conditions.

The CEO of Novo Nordisk has publicly defended the company's decision to sue rival Eli Lilly. The lawsuit concerns Eli Lilly's advertising practices for its weight-loss drug, with Novo Nordisk asserting that competition must be fair.

The United Kingdom has become the first European country to approve Eli Lilly's oral drug 'Orforglipron' for weight management and diabetes treatment.

Eli Lilly's weight-loss pill Foundayo has received approval in the U.K., marking its first approval outside the U.S. and intensifying its competition with Novo Nordisk's Wegovy.

The competitive landscape between Eli Lilly and Novo Nordisk is increasingly defined by their manufacturing capabilities for GLP-1 drugs.

A summary of notable healthcare news for the week highlights developments concerning major pharmaceutical companies Eli Lilly, Novo Nordisk, and Pfizer.

An analysis compares Eli Lilly and Viking Therapeutics to determine which company offers a better investment opportunity in GLP-1 stocks.

Pharmaceutical giants Eli Lilly and Novo Nordisk have successfully defeated an antitrust lawsuit concerning their market position in GLP-1 drugs.

This report provides a compilation of analyst estimates and ratings for Eli Lilly stock, offering insights into Wall Street's sentiment and price targets for the pharmaceutical company.

Eli Lilly's stock experienced a significant jump following strong GLP-1 sales, further widening its lead over competitor Novo Nordisk.

Pharmaceutical company Eli Lilly has raised its expectations for 2026, a move that positions it as a strong rival to Novo Nordisk, according to The Copenhagen Post.

AMD and SpaceX are pulling back after earnings. But Eli Lilly is jumping after crushing estimates.

Despite Novo Nordisk raising its forecast, Wall Street remains unconvinced about the sustainable growth path for its obesity business, citing intensifying competition from Eli Lilly.

Eli Lilly & Co.'s stock, consistently trading above $1,000 per share due to the success of its obesity drugs, is now seen by some analysts as a prime candidate for a stock split.

An analysis compares Abbott Laboratories and Eli Lilly to determine which healthcare stock presents a better investment opportunity for 2026.

JPMorgan notes that one of the market's 'most durable growth' sectors has been overlooked in favor of AI, listing Eli Lilly, AbbVie, and Danaher Corporation as top stock picks in that sector.

Analysts are highlighting additional factors, beyond its popular weight loss medications, that make Eli Lilly stock an attractive investment opportunity.

Eli Lilly has committed $2.8 billion to a new venture, signaling a strategic move to expand its portfolio beyond its highly successful GLP-1 drugs.

Pharmaceutical company Eli Lilly announced that its experimental obesity drug, retatrutide, achieved primary objectives in two more Phase III clinical trials, with patients losing over 20% of their weight.

Scribe, a company backed by pharmaceutical giants Eli Lilly and Sanofi, experienced a significant surge in its public market debut.

A billionaire has made $360 million by selling his psychedelic company to pharmaceutical giant Eli Lilly. This acquisition highlights growing interest and investment in the psychedelic medicine sector.

Eli Lilly announced plans to seek FDA approval for its next-generation obesity drug in early 2027, following successful results from its latest clinical trials.

Novo Nordisk verklagt US-Rivalen Eli Lilly +++ Indischer Konzern könnte bei VW-Tochtergesellschaft einsteigen +++ Bitburger profitiert von Fußball-WM  +++ Neuigkeiten im Unternehmen-Liveblog.

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging misleading advertising claims related to GLP-1 medications.

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley signals a significant 'buy signal' for the market of psychedelic drugs aimed at treating mental health conditions, marking Big Pharma's growing acceptance of these previously stigmatized medications.

Eli Lilly is set to acquire AtaiBeckley for a sum of up to $3.8 billion, marking the latest venture by a major pharmaceutical company into the psychedelic drug market.

AtaiBeckley's stock surged after Eli Lilly announced an acquisition deal potentially worth up to $3.8 billion.

An analysis compares Johnson & Johnson and Eli Lilly and Company to determine which pharmaceutical giant's stock presents a better investment opportunity in 2026.

AtaiBeckley's stock surged following reports that pharmaceutical giant Eli Lilly is poised to acquire the psychedelic drug developer.

Despite a 30 percent surge in Novo Nordisk's stock after significant losses, analysts are reportedly more confident in rival Eli Lilly for the coming years, even with Novo Nordisk's lead in the "pill war." The article reviews key figures explaining this skepticism.

VivoSim has received a $5 million milestone payment from Eli Lilly and projects over 500% revenue growth for fiscal year 2027.

A new trend is raising concerns about potential negative impacts on Eli Lilly's position in the lucrative billion-dollar obesity drug market.

An article provides an honest take on whether investors should consider purchasing stock in the pharmaceutical company Eli Lilly.

A prediction has been made regarding Eli Lilly's stock, forecasting a specific price target for the pharmaceutical company's shares by the end of 2026.

While Eli Lilly and Novo Nordisk are prominent players in the GLP-1 market, new analysis suggests that other stocks could offer even better investment opportunities in this rapidly growing sector. Investors are exploring broader options within the GLP-1 boom.

Eli Lilly's stock performance is being observed as the company faces high demand for its products.

Several stocks are being highlighted as strong investment opportunities for retirement, including those in the AI sector like Vertiv, Seagate, and Quanta. Eli Lilly and Rocket Lab are also mentioned as potential long-term holdings.

Johnson & Johnson is reportedly withdrawing from the lucrative $100 billion obesity market. This strategic decision raises questions about its long-term investment potential compared to competitors like Eli Lilly.

Eli Lilly and Company has named Sebastian Iovan as the new General Manager for its Romania Cluster, effective July 1, 2026. Iovan will oversee commercial, medical, and operational activities in Romania and Bulgaria.

US lawmakers are reportedly pressing pharmaceutical giant Eli Lilly for information regarding its drug trials conducted in China, specifically those tied to military-linked hospitals.

Eli Lilly and Regeneron have been selected by the FDA to participate in a new pilot program designed to boost U.S. drug manufacturing. This initiative aims to speed up the review process for new manufacturing facilities.

Eli Lilly's Gateway Labs in San Diego serves as a biotech startup factory, where researchers and scientists collaborate on ongoing projects and share insights.

Eli Lilly (LLY) announced positive Phase 3 results for its Jaypirca combination therapy in patients with relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Healthcare stocks, including AbbVie, Eli Lilly, and Johnson & Johnson, are reaching all-time highs as investors shift their focus from the technology sector to biopharmaceuticals.

Pharmaceutical company Eli Lilly is celebrating its 150th anniversary, marking a journey from the first commercialization of insulin to its current innovative therapies.

Eli Lilly announced that its drugs Foundayo and Zepbound will be accessible to Medicare Part D beneficiaries starting July 1.

Eli Lilly and Company is reportedly strengthening its pain management strategy through a new acquisition of a biotech firm.

The CEO of Eli Lilly and Company (LLY) shares insights on how GLP-1 medications are expected to reshape various aspects of America.

Eli Lilly, maker of Mounjaro, is deploying its weight-loss drug profits to create an 'App Store' for scientists, collaborating with small biotechs to utilize AI as a tool for drug discovery.

Several pharmaceutical companies, including Eli Lilly, Novo Nordisk, and Novartis, are being highlighted as leading investment opportunities in the longevity and anti-aging sector. These companies are recognized for their potential in developing treatments and technologies aimed at extending lifespan and combating aging.

Pfizer's dividend yield is reportedly ten times larger than Eli Lilly's, leading to questions about which stock offers a better return for income-focused investors.

A prediction suggests that pharmaceutical company Eli Lilly's stock will trade at $1,200 by a certain date. This article provides analysis on the potential future performance of the company's shares.

Reports are surfacing regarding the latest developments within Eli Lilly and Company's drug pipeline, with early signals indicating potential progress or shifts in their pharmaceutical research and development.

Eli Lilly is once again making significant investments, while an insider purchase at Broadcom has drawn attention from investors, as highlighted in a daily market update.

An analysis compares Eli Lilly and Novo Nordisk to determine which company offers a better investment opportunity in the obesity drug market.

Shares of Eli Lilly continue to shine while other major pharmaceutical and healthcare companies report struggling growth metrics amid shifting market dynamics.

Eli Lilly is projected to have significant revenue growth, with analysts seeing substantial upside potential for the pharmaceutical company's stock.

Analysts predict that pharmaceutical giant Eli Lilly could emerge as one of the biggest winners of the next decade. The forecast is based on various factors contributing to the company's potential growth.

Investors are watching Eli Lilly (LLY) stock for a potential stock split.

An analysis provides recommendations on whether to buy, sell, or hold stocks for pharmaceutical giants Eli Lilly, Novo Nordisk, and Merck.

Eli Lilly and Johnson & Johnson shares saw a bounce after new data was released, while software stocks gave up their gains from the previous week.

OmniAb has revised its 2026 cash outlook upwards after finalizing a significant deal with pharmaceutical giant Eli Lilly.

The Tribeca Film Festival, in collaboration with Eli Lilly, premiered three short films titled 'Reconstructing Charlie', 'Run It Back', and 'Do I Know You From Somewhere?' as part of its 'Vital Stories' program.

Eli Lilly's weight-loss pill has successfully established its first market presence in Europe, marking a significant expansion for the pharmaceutical company.

An analysis compares Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) to determine which pharmaceutical giant is gaining an advantage in the rapidly expanding $100 billion obesity drug market.

Financial commentator Jim Cramer has identified pharmaceutical giants like Johnson & Johnson (JNJ) and Eli Lilly (LLY) as strong investment opportunities. He highlights these companies as innovative plays outside the traditional technology sector.

Eli Lilly (LLY) announced significant growth in its latest financial report and subsequently raised its future outlook, indicating strong performance.

Bank of America suggests that Eli Lilly has a market opportunity outside the U.S. that could potentially surpass its domestic market size.

A financial analysis predicts Eli Lilly's stock price in 2027, with Morgan Stanley reportedly agreeing with the assessment.

Yahoo Finance provides a summary of Eli Lilly and Company's second-quarter 2026 earnings call.

Despite strong fundamentals, healthcare stocks are reportedly being overlooked by investors, with analysts recommending several companies including Eli Lilly and McKesson.

An analysis of Eli Lilly's stock performance focuses on a key question arising from its otherwise strong earnings report and its implications for shares.

Eli Lilly's stock saw a significant increase after the company released a stronger revenue outlook, primarily attributed to the strong performance and future potential of its obesity drug portfolio.

Several major companies, including SpaceX, AMD, Eli Lilly, and Disney, are experiencing significant movements in premarket trading, indicating potential volatility for the day's market open.

An analysis questions whether Eli Lilly maintains its leadership in the $150 billion obesity drug market.

Novo Nordisk is gaining momentum with its Wegovy weight-loss pill, maintaining its lead against Eli Lilly's recently launched Foundayo in the competitive obesity treatment market.

A new prediction suggests that pharmaceutical giant Eli Lilly could achieve a market capitalization of $2 trillion by the year 2031, highlighting its projected growth.

Eli Lilly has expanded its manufacturing agreement with Resilience for the production of KwikPen devices.

An analysis delves into the extent of investment in Eli Lilly (LLY), examining the factors driving its market valuation and investor interest. The report assesses the company's current position and future prospects.

Eli Lilly is set to acquire AtaiBeckley for $2.8 billion, a move that has drawn attention from investors like Cathie Wood, who suggests another psychedelic drug stock might be a better investment.

The article explores how Eli Lilly, founded in 1876, revolutionized the pharmaceutical industry by introducing scientific rigor to a market previously dominated by unproven remedies.

Jim Cramer has expressed his desire for Novo Nordisk A/S (NYSE:NVO) to focus on market competition with Eli Lilly rather than engaging in legal battles.

Danish manufacturer Novo Nordisk announced it is seeking a provisional injunction from a US court to immediately block advertisements for obesity and diabetes drugs by American company Eli Lilly. The lawsuit involves popular medications like Wegovy, Ozempic, Mounjaro, and Zepbound.

Eli Lilly's next-generation weight-loss shot has cleared another regulatory hurdle, signaling progress in its development. Meanwhile, Wall Street experienced a stumble, partly influenced by surging oil prices.

Eli Lilly (LLY) stock is demonstrating strong momentum, but analysts are questioning its current valuation and price point.

Financial analyst Jim Cramer has reiterated his support for Eli Lilly, even as the pharmaceutical company faces a GLP-1 lawsuit from a rival, explaining his reasons to investors.

Claude AI has reportedly expressed disagreement with President Trump concerning Eli Lilly (LLY) stock.

Significant business deals involving major companies such as Eli Lilly, PayPal, and Uber were highlighted this week, indicating active corporate transactions.

AtaiBeckley (ATAI) stock has surged to a four-year high following reports of a $3.8 billion merger with pharmaceutical giant Eli Lilly. This significant deal is expected to have a major impact on both companies.

A trend of major pharmaceutical companies investing in psychedelic drugs is emerging, with Eli Lilly making a significant deal worth up to $3.8 billion with AtaiBeckley, signaling a potential buyout spree in the sector.

GH Research shares have gained amidst optimism surrounding a potential deal between Eli Lilly and Atai Life Sciences, which could impact the company.

Shares of psychedelic drugmaker AtaiBeckley surged by 66% following reports of potential buyout discussions with pharmaceutical giant Eli Lilly.

Reports indicate that Eli Lilly's new obesity pill is trailing behind Novo Nordisk's competing product, even three months after its launch, suggesting a challenging market entry.

Cathie Wood's Ark Invest has adjusted its portfolio before Q2, acquiring shares in SpaceX, Eli Lilly, and Meta, while paring down holdings in AMD and Roku.

Politicians in Zuid-Holland, Netherlands, have approved a contribution of at least €31 million for traffic measures in Katwijk to facilitate the construction of an Eli Lilly factory and thousands of new homes.

Eli Lilly's stock price surged to a new record high today, reflecting strong investor confidence in the pharmaceutical company.

Jim Cramer expresses a contrarian view on Eli Lilly, suggesting that the market's perception of the company's story being "played out" is incorrect.

An analysis compares Eli Lilly and Teva Pharmaceutical stocks to determine which might be a better investment opportunity by the year 2026.

Key developments in the healthcare sector this week highlighted major pharmaceutical and medical device companies, including Abbott, AstraZeneca, and Eli Lilly, as reported in industry headlines.

Eli Lilly (LLY) is being discussed as one of billionaire investor Cliff Asness’s best healthcare stock picks, highlighting its potential in the market.

American pharmaceutical giant Eli Lilly is projected to reach nearly $140 billion in revenue by 2032, largely driven by its weight-loss medications. The company's stock market valuation has nearly doubled that of Roche and Novartis combined.

This article discusses whether investors should pursue the recent breakout in Eli Lilly's stock price.

Hedge funds are reportedly evaluating top AI-powered healthcare stocks, with Eli Lilly and Company (LLY) and Regeneron Pharmaceuticals, Inc. (REGN) being highlighted as potential investment opportunities in this sector.

Japanese pharmaceutical company Daiichi Sankyo is increasing its investments in Germany, a move that stands in contrast to recent decisions by other major drug manufacturers like Eli Lilly and Boehringer Ingelheim to scale back their German operations.

Eli Lilly (LLY) has announced the acquisition of Centessa Pharmaceuticals, aiming to further develop Orexin Receptor 2 Agonists for its pharmaceutical pipeline.

Eli Lilly and Company (LLY) has been highlighted as one of the top ten reliable dividend stocks recommended for long-term investment strategies.

Absci's stock saw a significant surge following investments from Eli Lilly and private equity firms.

Pharmaceutical giants Eli Lilly and Bayer have voiced strong criticism against Germany's expenditure on new medicines, indicating support for the US pushback on drug price legislation.

Eli Lilly currently holds a dominant position in the obesity drug market, while Pfizer has made strategic investments to compete in the sector in the near future.

Manufacturer Eli Lilly has offered a significant price reduction for the drug Mounjaro, which may result in the medicine being deemed cost-effective by the National Centre for Pharmacoeconomics.

Pharmaceutical giant Eli Lilly has made seven acquisitions in the past three months, prompting analysis on which of these deals will significantly impact the company's future.

The Katwijk municipal council has given provisional approval for the construction of an Eli Lilly pharmaceutical factory. This decision marks a significant step towards bringing the new drug manufacturing facility to the area.

Jim Cramer provided varied advice on several stocks, expressing bearish sentiment on fuboTV and Adobe, while recommending Constellation Energy and Credo. He also advised buying Cadence if its price drops and acknowledged past failures with HawkEye 360.

Eli Lilly and Co.'s drug Retatrutide is being evaluated for its potential to further solidify the company's dominant position in the weight loss medication market.

An article discusses whether it is an opportune time to invest in Eli Lilly stock or if investors should wait for a dip.

An article discusses whether Eli Lilly can maintain its current profit margins, analyzing the financial health of the pharmaceutical giant.

Billionaire investor Ken Griffin has significantly increased his holdings in Eli Lilly stock, prompting questions on whether others should follow suit.

Major pharmaceutical companies Novartis, Eli Lilly, and Bristol Myers Squibb are reportedly showing interest in a clinical-stage cancer therapy, indicating potential future acquisitions or partnerships in the oncology space.

Eli Lilly and Company's weight-loss pill has secured its initial approval in Europe. Despite this milestone, Novo Nordisk A/S continues to hold a dominant position in the weight-loss drug market.

OmniAb has announced a partnership with Eli Lilly to collaborate on an ion channel program, aiming to advance research and development in the field.

This week's notable healthcare headlines highlight developments concerning companies such as Eli Lilly, Hims & Hers Health, and Merck.

An Eli Lilly executive, Patrik Jonsson, stated that obesity drugs are the hottest business in the pharmaceutical industry and predicted an end to obesity, while also criticizing Finland's current treatment approach.

The article explores whether Veeva Systems Inc.'s AI platform can keep pace with the explosive growth experienced by Eli Lilly and Company.

Граничните проверки на ЕС удвояват опашките на големите летища Времето за изчакване на две големи европейски летища се е удвоило това лято в сравнение с миналата година, след хаотичното въвеждане от…

This article compares Eli Lilly and Novo Nordisk, analyzing which company is better positioned to navigate America’s new drug manufacturing policies.

Novo Nordisk is making a significant push for its Wegovy pill, which has been a strong competitor against Eli Lilly. However, following a supply crisis in 2021, analysts are questioning whether production can keep pace with the high demand.

Several companies, including Oscar Health, Optimum Communications, and Ormat Technologies, have released highlights from their second-quarter earnings calls. These reports provide updates on their financial performance and business operations for the recent quarter.

The gap between Eli Lilly and Novo Nordisk is expanding after their recent earnings reports, with Lilly strengthening its position in the obesity treatment race while Novo Nordisk works to regain market share.

Eli Lilly's stock experienced a notable climb today, prompting analysis into the factors contributing to its positive market performance.

Eli Lilly is teaming up with CVS regarding weight-loss drugs, a development that has generated an LLY stock alert.

A commentary highlights Novo Nordisk's 4.0% growth compared to Eli Lilly's 48%, examining how the Danish pharmaceutical giant's ownership structure, caught between Danish foundation capitalism and American stock market capitalism, may both protect and hinder its expansion.

Eli Lilly's stock experienced a rise after the company reported revenues that exceeded expectations and subsequently increased its financial outlook.

Eli Lilly's stock is up 7% in 2026, with analysts pointing to major upcoming catalysts that could continue to drive its rally.

The competition in the obesity drug market is heating up as pharmaceutical giants Novo Nordisk and Eli Lilly vie for market dominance, with Novo Nordisk making strides to catch up.

Eli Lilly's stock has seen a significant surge, while Novo Nordisk's has crashed, with a key financial metric explaining the divergence in their market performance.

An analysis comparing Pfizer Inc. and Eli Lilly and Company from an investment perspective, focusing on growth versus value plays in the pharmaceutical sector.

An analysis highlights a particular stock that is significantly outperforming pharmaceutical giants Eli Lilly, Johnson & Johnson, and AbbVie. The article likely delves into the reasons for its strong performance.

An analysis explores whether investing in Eli Lilly stock effectively diversifies an investment portfolio, examining its role within broader market strategies.

This week's notable healthcare headlines highlight developments concerning major pharmaceutical and healthcare companies, including Eli Lilly, Molina Healthcare, and Roche. The report provides a general overview of the sector's focus.

Scribe Therapeutics, a company backed by Eli Lilly, saw its stock jump 67% following an upsized initial public offering.

Eli Lilly's highly anticipated weight loss drug has demonstrated significant efficacy in trials, with participants losing an average of 56 pounds.

Danish pharmaceutical giant Novo Nordisk has filed a lawsuit against competitor Eli Lilly, escalating the battle for the lucrative weight-loss drug market.

An analysis of Eli Lilly's stock performance, examining the role of investor confidence in its current valuation and market trajectory.

Novo Nordisk, the maker of Ozempic, has initiated legal action against rival pharmaceutical company Eli Lilly, alleging that its advertisements are misleading, a claim Eli Lilly denies.

Eli Lilly is fundamentally changing the pharmaceutical business, reinventing the industry with its innovative approaches. The company's strategies are significantly impacting the traditional pharma landscape.

Eli Lilly's stock continues to surge due to reasons that are often overlooked by investors, which are unrelated to its popular weight loss drugs.

UBS has significantly adjusted its stock target for Eli Lilly, indicating a strong re-evaluation of the pharmaceutical company's market prospects. This reset reflects new analysis or market conditions impacting the stock.

Eli Lilly has announced its intention to acquire AtaiBeckley, a psychedelic drugmaker, in a deal valued at $2.8 billion, signaling a significant move into the emerging field of psychedelic therapeutics.

Shares of AtaiBeckley experienced a significant increase following reports of potential takeover discussions with pharmaceutical giant Eli Lilly.

Eli Lilly, the world's largest drugmaker, is making significant investments in preventive medicines, aiming to reinvent the pharmaceutical business by learning from big tech strategies.

VivoSim anticipates a revenue growth exceeding 500% by fiscal year 2027 and has received a $5 million milestone payment from pharmaceutical giant Eli Lilly.

The financial value of Eli Lilly's weight-loss drugs to investors is being assessed, highlighting their potential impact on the company's market performance.

An article explores whether it is still a good time for investors to buy shares in pharmaceutical giant Eli Lilly.

An analysis compares AbbVie and Eli Lilly to determine which pharmaceutical company offers a better dividend stock for long-term investment over the next decade.

Eli Lilly's stock has hit a new all-time high, prompting discussions on whether its current valuation makes it too expensive for new investors.

An analysis pits "Dividend King" Johnson & Johnson against "Growth Giant" Eli Lilly, evaluating their respective investment merits.

Eli Lilly's stock reached new highs following news of GLP-1 drug inclusion in Medicare and the announcement of significant positive results.

A House committee has launched an investigation into several pharmaceutical companies, including Eli Lilly, Bristol, Merck, and AbbVie, regarding their clinical trials in China, particularly those tied to military-linked hospitals and facilities in Xinjiang, citing biotech risks.

Innovent Biologics and Eli Lilly have partnered to commercialize Verzenios (abemaciclib) in China, expanding access to the cancer treatment in the region.

Eli Lilly and Company and Kulicke and Soffa Industries have both experienced significant stock gains over the past month, with Eli Lilly up over 6% and Kulicke and Soffa Industries up over 13%. Investors are watching to see if these positive trends will continue.

Eli Lilly (LLY) and BioArctic AB have announced a new research and collaboration agreement, aiming to advance scientific discoveries and develop new treatments.

Eli Lilly's stock experienced a significant jump today, reaching a new all-time high.

New GLP-1 weight-loss medications from Novo Nordisk and Eli Lilly are expected to increase consumer demand, potentially posing a challenge for employer-sponsored health insurance coverage.

A stock tracker following Nancy Pelosi's investments flagged Eli Lilly and Nokia as companies to watch, particularly after praise from Donald Trump.

An analysis compares Eli Lilly and Viking Therapeutics, evaluating which GLP-1 stock presents a better investment opportunity.

Eli Lilly and Company has announced a dividend of $1.73 per share to its shareholders.

Pharmaceutical company Eli Lilly has reached a market capitalization of $1 trillion, a significant milestone reflecting its growth and success in the industry.

An article outlines three reasons why investors might consider buying Eli Lilly stock, highlighting its potential for growth.

Eli Lilly and Company (LLY) has been highlighted by investor Ray Dalio as one of the best growth stocks currently available for purchase.

Investors are closely monitoring Eli Lilly stock as the company develops new drugs, with particular attention on a key metric that has recently disappeared from reports.

Eli Lilly's most popular drugs are reportedly facing a quiet new threat, potentially impacting the pharmaceutical giant's market position.